Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels
AssigneeHoffmann-La Roche Inc.
InventorHerman Kempen
Life of this patent
Estimating the term…
Abstract
9-methyl-4-phenyl-6H-thieno3,2-f!-s-triazolo4,3-a!1,4!diazepine for the treatment and prevention of illnesses which are caused by low plasma apolipoprotein A-I levels as coronary coronary disease.
Claims16
A method for preventing coronary artery disease which comprises administering an effective amount of the compound 9-methyl-4-phenyl-6H-thieno3,2-f!-s-triazolo4,3-a!1,4!diazepine to an individual not afflicted with coronary artery disease.
A method for treating coronary artery disease which comprises administering an effective amount of the compound 9-methyl-4-phenyl-6H-thieno3,2-f!-s-triazolo4,3-a!1,4!diazepine to an individual afflicted with coronary artery disease.
Dependencies are inferred from the claim text.